Pemphigus Treatment Protocols
On this page
Direct answer
Pemphigus treatment rests on systemic corticosteroids, which control blistering quickly, combined with a steroid-sparing adjuvant so that the steroid dose can be tapered safely. Rituximab, pulsed dexamethasone-cyclophosphamide, IVIG and plasmapheresis are reserved for moderate-to-severe or refractory disease. Topical steroids suffice only for mild, localised lesions, and the aim throughout is control with the least cumulative steroid exposure.
What you must remember
- First line: systemic corticosteroid, usually prednisolone at a high starting dose, is the backbone of initial control.
- Steroid-sparing adjuvant: azathioprine, mycophenolate mofetil, methotrexate or cyclophosphamide, added early so prednisolone can be tapered sooner.
- DCP regimen: pulsed dexamethasone with intravenous cyclophosphamide, used for severe or steroid-resistant disease to limit continuous steroid exposure, and widely used as a primary regimen in India.
- Rituximab: anti-CD20 therapy for moderate-to-severe or refractory disease, increasingly used early in recent guidelines, always given alongside corticosteroids and subject to availability and cost.
- IVIG and plasmapheresis: rescue options for severe or refractory pemphigus when standard therapy fails.
- Topical steroids: potent preparations for mild, localised lesions, sparing systemic exposure.
- Prophylaxis: cotrimoxazole against Pneumocystis, plus calcium, vitamin D and gastric protection during prolonged steroid therapy.
- Monitoring: the Pemphigus Disease Area Index tracks activity, so relapse is judged against a score rather than blister count alone.
A staged approach to control and taper
Pemphigus treatment is staged, with the aim of controlling blistering quickly while limiting the cumulative steroid dose. The steps below follow the sequence most textbooks describe, and each one has a clear trigger that can be recited in an exam.
- Grade the disease. Classify it as mild, moderate or severe by extent, mucosal involvement and the effect on eating and fluid balance.
- Start systemic steroids. Prednisolone at a high dose controls blistering, with topical steroids alone reserved for mild, localised disease.
- Add a steroid-sparing agent. Azathioprine, mycophenolate mofetil, methotrexate or cyclophosphamide, started early, allow the steroid to be tapered sooner.
- Escalate for severe or refractory disease. Use the dexamethasone-cyclophosphamide pulse regimen, rituximab, IVIG or plasmapheresis when the response is poor.
- Taper and maintain. Reduce corticosteroids slowly once control is achieved, and keep the adjuvant until remission is established.
- Monitor and prevent harm. Watch for infection, diabetes, osteoporosis and cytopenias, and give Pneumocystis prophylaxis during high-dose steroid therapy.
Where candidates lose marks
Treatment questions often test sequencing and safety rather than drug names alone.
- Trap: stopping corticosteroids abruptly once the blisters heal Correct: taper slowly, since abrupt withdrawal risks relapse, and keep the adjuvant for longer.
- Trap: using rituximab as a replacement for corticosteroids Correct: rituximab is combined with corticosteroids, which remain the backbone of initial control.
- Trap: treating generalised or mucosal disease with topical steroids alone Correct: systemic therapy is needed for widespread or mucosal disease, whereas topical measures suit localised lesions only.
Frequently asked questions
Which steroid-sparing agents are used in pemphigus?
Azathioprine, mycophenolate mofetil, methotrexate and cyclophosphamide are the commonest steroid-sparing agents in pemphigus. Their role is to allow prednisolone to be tapered sooner, which limits corticosteroid toxicity over time.
What is the dexamethasone-cyclophosphamide pulse regimen in pemphigus?
The dexamethasone-cyclophosphamide pulse is an intermittent regimen used for severe or steroid-resistant pemphigus, combining the two drugs in pulsed doses. It reduces continuous corticosteroid exposure and is usually considered when standard therapy fails.
When is rituximab used in pemphigus?
Rituximab is used for moderate-to-severe pemphigus and for disease that has not responded to standard therapy, usually alongside corticosteroids. Its use depends on availability and cost, which often limit access in many settings.
Why is Pneumocystis prophylaxis given in pemphigus?
Patients on high-dose corticosteroids, especially with added immunosuppressants, are at risk of Pneumocystis pneumonia. Cotrimoxazole is commonly used as prophylaxis, with its duration guided by the steroid dose and overall risk.
Which scoring tool tracks disease activity in pemphigus?
The Pemphigus Disease Area Index scores activity by counting lesions across skin and mucosal sites, and it guides treatment decisions. Serial scoring helps separate true relapse from slow healing of established lesions.